Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

117
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
117
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

496
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
496
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

196
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
196
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

574
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
574
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

560
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
560
Ethical Dilemmas II01:30

Ethical Dilemmas II

1.1K
Resolving an ethical dilemma in healthcare involves a systematic approach that considers every aspect of the issue, respecting both the patient's needs and values and the healthcare professional's ethical obligations. Here are potential steps to resolve an ethical dilemma:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demystifying responding to peer reviews: Turning feedback into success.

Journal of the American Pharmacists Association : JAPhA·2025
Same author

Endocarditis.

Primary care·2024
Same author

The effect of a translating research into practice (TRIP)--cancer intervention on cancer pain management in older adults in hospice.

Pain medicine (Malden, Mass.)·2012
Same author

Preventing unintended pregnancy: pharmacists' roles in practice and policy via partnerships.

Journal of the American Pharmacists Association : JAPhA·2010
Same author

The cancer pain practice index: a measure of evidence-based practice adherence for cancer pain management in older adults in hospice care.

Journal of pain and symptom management·2010
Same author

Assessing and treating pain in hospices: current state of evidence-based practices.

Journal of pain and symptom management·2010

Related Experiment Video

Updated: Jul 11, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K

Dementia: Management and Controversies in Management.

John Swegle1

  • 1University of Iowa College of Pharmacy, Iowa City, IA.

FP Essentials
|November 17, 2023
PubMed
Summary

Effective dementia management prioritizes education and non-drug therapies. While some medications exist, their use requires careful consideration of individual needs and evidence, especially for newer treatments like aducanumab.

Area of Science:

  • Neurology
  • Geriatrics
  • Pharmacology

Background:

  • Dementia care necessitates personalized patient education and realistic expectations.
  • Vitamins and supplements for memory enhancement lack supporting evidence.
  • Nonpharmacological interventions are crucial throughout all dementia stages.

Purpose of the Study:

  • To outline current evidence-based strategies for dementia management.
  • To discuss the role of pharmacotherapy and nonpharmacotherapy in dementia care.
  • To address challenges in managing behavioral and psychological symptoms of dementia.

Main Methods:

  • Review of current literature on dementia pharmacotherapy and nonpharmacotherapy.
  • Analysis of guidelines for managing cognitive and behavioral symptoms.

More Related Videos

A Cognitive Paradigm to Investigate Interference in Working Memory by Distractions and Interruptions
10:38

A Cognitive Paradigm to Investigate Interference in Working Memory by Distractions and Interruptions

Published on: July 16, 2015

13.6K
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K
A Cognitive Paradigm to Investigate Interference in Working Memory by Distractions and Interruptions
10:38

A Cognitive Paradigm to Investigate Interference in Working Memory by Distractions and Interruptions

Published on: July 16, 2015

13.6K
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.4K
  • Evaluation of newer treatments like aducanumab.

    • Main Results:

    • Initial pharmacotherapy often includes cholinesterase inhibitors and memantine, guided by patient-specific factors.
    • Nonpharmacotherapy is the primary approach for behavioral and psychological symptoms.
    • Newer treatments like aducanumab show limited evidence for cognitive benefits and face access barriers.

    Conclusions:

    • Dementia management requires individualized approaches, balancing pharmacotherapy and nonpharmacotherapy.
    • Caregiver input and functional assessments are vital for evaluating treatment efficacy.
    • Careful consideration of risks, benefits, and costs is essential for all dementia treatments.